CSM Advisors LLC Purchases 5,052 Shares of Stryker Corporation $SYK

CSM Advisors LLC lifted its position in shares of Stryker Corporation (NYSE:SYK) by 871.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 5,632 shares of the medical technology company’s stock after acquiring an additional 5,052 shares during the quarter. CSM Advisors LLC’s holdings in Stryker were worth $2,081,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Clayton Financial Group LLC purchased a new stake in Stryker during the third quarter valued at about $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the third quarter worth about $27,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Stryker in the second quarter valued at approximately $28,000. Kilter Group LLC bought a new stake in shares of Stryker in the second quarter valued at approximately $29,000. Finally, Howard Hughes Medical Institute purchased a new stake in shares of Stryker during the 2nd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the transaction, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.20% of the company’s stock.

Stryker Stock Up 3.9%

SYK stock opened at $349.89 on Tuesday. The company’s 50 day moving average is $365.22 and its 200 day moving average is $367.06. The stock has a market cap of $133.90 billion, a price-to-earnings ratio of 41.65, a price-to-earnings-growth ratio of 1.97 and a beta of 0.85. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. Stryker Corporation has a 1-year low of $328.23 and a 1-year high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $7.17 billion during the quarter, compared to analyst estimates of $7.12 billion. During the same period in the previous year, the business posted $4.01 earnings per share. Stryker’s revenue for the quarter was up 11.4% on a year-over-year basis. Sell-side analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s payout ratio is currently 41.90%.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Sanford C. Bernstein increased their target price on Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research report on Friday, January 9th. Truist Financial cut their price target on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a research report on Tuesday, January 6th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $465.00 price objective on shares of Stryker in a research note on Wednesday, March 4th. Fourteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $428.61.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.